The earnings call reflected a balanced sentiment. While Recursion highlighted strong financials, successful platform evolution, and significant partnerships, they also faced challenges with program discontinuations and limited success in certain trials. The company's focus on pipeline advancements and strategic partnerships suggests a cautiously optimistic outlook.

Company Guidance -

Q3 2025

In the recent earnings call, Chris Gibson, CEO of Recursion, highlighted the company's strategic focus on refining its R&D portfolio and leveraging its Recursion Operating System 2.0. The company is prioritizing over five clinical and preclinical programs, with a particular emphasis on oncology and rare diseases, aiming for first or best-in-class potential. Recursion has successfully brought in more than $450 million through collaborations, including a recent fourth program option from Sanofi. The company aims to validate hypotheses faster, generate candidates with fewer synthesized molecules, and reduce costs while accelerating development. Additionally, the company remains focused on disciplined capital allocation, maintaining a cash runway into mid-2027, with a projected operational budget of $450 million or less for 2025.

Strong Financial Position

Recursion ended the quarter with $509 million in cash and expects a cash runway into mid-2027. The company has brought in $450 million from partnerships to date.

Successful Platform Evolution

The evolution from Recursion 0.1 to Recursion 2.0 has enabled the company to validate hypotheses more quickly, generate candidates with fewer molecules synthesized, and spend less while moving faster.

Partnership Milestones

Recursion has achieved four milestones with Sanofi and a major milestone with Roche, highlighting strong external validation of their approach.

Pipeline Advancements

The company is advancing over five internally developed programs with first or best-in-class potential, targeting unmet needs with a clear and efficient path to development.

Recursion Pharmaceuticals (RXRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RXRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.32 / -	-0.34	―	―	―
Aug 05, 2025	2025 (Q2)	-0.35 / -0.41	-0.4	-2.50% (>-0.01)		―
May 05, 2025	2025 (Q1)	-0.52 / -0.50	-0.39	-28.21% (-0.11)
Feb 28, 2025	2024 (Q4)	-0.41 / -0.53	-0.42	-26.19% (-0.11)	―
Nov 06, 2024	2024 (Q3)	-0.33 / -0.34	-0.43	20.93% (+0.09)	―	―
Aug 08, 2024	2024 (Q2)	-0.38 / -0.40	-0.38	-5.26% (-0.02)
May 09, 2024	2024 (Q1)	-0.42 / -0.39	-0.34	-14.71% (-0.05)	―
Feb 27, 2024	2023 (Q4)	-0.45 / -0.42	-0.31	-35.48% (-0.11)	―
Nov 09, 2023	2023 (Q3)	-0.39 / -0.43	-0.35	-22.86% (-0.08)	―	―
Aug 08, 2023	2023 (Q2)	-0.38 / -0.38	-0.38	0.00% (0.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RXRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2025	$5.70	$4.76	-16.49%
Feb 28, 2025	$7.67	$7.51	-2.09%
Nov 06, 2024	$6.97	$6.93	-0.57%
Aug 08, 2024	$6.37	$6.64	+4.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Recursion Pharmaceuticals (RXRX) report earnings?

Recursion Pharmaceuticals (RXRX) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Recursion Pharmaceuticals (RXRX) earnings time?

Recursion Pharmaceuticals (RXRX) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RXRX EPS forecast?

RXRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.32.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing